The effect of biologic therapy for immune-mediated inflammatory diseases on clinical outcomes of COVID-19 in the Greater Houston Area:a retrospective chart review-Supplemental Data

Published: 5 January 2022| Version 1 | DOI: 10.17632/kbzx8hbvgh.1
Contributor:
Kevin Lee

Description

Supplemental data for the manuscript titled "The effect of biologic therapy for immune-mediated inflammatory diseases on clinical outcomes of COVID-19 in the Greater Houston Area: a retrospective chart review" published in the Journal of the American Academy of Dermatology by Lee KP, B.S.1, Koshelev MV, M.D., Ph.D.2, D3CODE Team3, and Pacha O, M.D.4. 1University of Texas at Houston McGovern Medical School, Houston, Texas 2Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas 3Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, University of Texas, MD Anderson Cancer Center, Houston, Texas 4Department of Dermatology, MD Anderson Cancer Center, Houston, Texas Supplemental Table 1 describes the baseline characteristics of patients on biologics with confirmed COVID-19. Supplemental Table 2 describes the susceptibility to COVID-19 based on the drug class of the biologics.

Files

Institutions

University of Texas MD Anderson Cancer Center, University of Texas Health Science Center at Houston

Categories

Dermatology, Epidemiology, Biologic Therapy, Immune-Mediated Illness, COVID-19

License